Nestle organic sales growth beats forecasts, says to review vitamins business

Nestle reported better-than-expected first-half organic sales growth of 2.9%, surpassing analyst forecasts, though total reported sales declined 1.8% to CHF 44.2 billion, significantly impacted by negative foreign exchange movements. The world's largest packaged food company maintained its 2025 outlook for improved organic growth and an underlying trading operating profit margin at or above 16%. Crucially, Nestle announced a strategic review of underperforming mainstream and value brands within its Vitamins, Minerals and Supplements business, signaling potential divestments to optimize its portfolio and address underperforming assets.

Analysis

Nestle's first-half results present a nuanced picture, with underlying operational strength masked by significant currency headwinds. The company reported a 2.9% organic sales growth, narrowly surpassing the 2.8% analyst consensus and indicating resilient consumer demand. However, total reported sales declined by 1.8% to 44.2 billion Swiss francs, primarily due to a substantial 4.7% negative impact from the strengthening Swiss franc. A key development is the strategic review of underperforming mainstream brands within its Vitamins, Minerals and Supplements business, including Nature’s Bounty and Puritan's Pride, signaling a potential divestment. This move aligns with management's stated focus on optimizing the portfolio towards premium brands to enhance profitability. Importantly, Nestle reaffirmed its 2025 outlook, projecting improved organic growth over 2024 and an underlying trading operating profit margin at or above 16%, providing a stable forward-looking anchor for investors.

Key Decisions for Investors

• Investors should look past the headline reported sales decline and focus on the positive organic growth, which better reflects the company's operational health, while continuing to monitor the significant impact of foreign exchange.
• The strategic review and potential divestment of underperforming vitamin brands should be viewed as a positive catalyst for improving the company's future growth and margin profile.
• With management reaffirming its 2025 guidance, the report provides a degree of stability, suggesting the long-term investment case remains intact despite the currency-induced revenue miss.